We serve Chemical Name:(4-Chloro-3,5-dimethylphenyl)boronic acid CAS:1056475-86-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(4-Chloro-3,5-dimethylphenyl)boronic acid
CAS.NO:1056475-86-5
Synonyms:3,5-Dimethyl-4-chlorophenylboronic acid
Molecular Formula:C8H10BClO2
Molecular Weight:184.42800
HS Code:2931900090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:40.46000
Exact Mass:184.04600
LogP:0.63660
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3,5-Dimethyl-4-chlorophenylboronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,5-Dimethyl-4-chlorophenylboronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-Dimethyl-4-chlorophenylboronic acid Use and application,3,5-Dimethyl-4-chlorophenylboronic acid technical grade,usp/ep/jp grade.
Related News: In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. 6H-Pyrrolo[2,3-g]quinazolin-4-amine, N-(3-bromophenyl)- manufacturers The Institute for Clinical and Economic Review (ICER) on Friday released its report examining the cost-effectiveness of Soliris, also known as eculizumab, as well as up-and-comer efgartigimod for patients with the myasthenia gravis. 2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)ethan-1-amine suppliers AZ’s chief financial officer and incoming Alexion head Marc Dunoyer acknowledged that the reimbursement infrastructure for rare disease drugs in China isn’t as advanced as it is in many developed economies. The rare disease market in China is still small, but there’s a growing recognition of its importance from authorities, he added. methyl ((2S,4S)-3,4-dibenzyl-2-oxido-1,3,2-oxazaphospholidin-2-yl)-L-alaninate vendor & factory.
